Table 2.
Sensitivities and specificities at the optimal cut-off values (and cut-offs for resulting in a sensitivity and specificity of at least 90% each), and area under the receiver operating characteristic curve (AUROC) for urinary S100/calgranulins and the S100A8/A9-to-S100A12 ratio (uCalR) to distinguish treatment-naïve dogs with transitional cell carcinoma (TCC)/prostatic carcinoma (PCA) from other groups of dogs (all dogs ≥6 years of age [n = 141])
| Parameter | AUROC† | Cut-off | Sensitivity | Specificity |
|---|---|---|---|---|
| Treatment-naïve TCC/PCA (n = 22) vs. UTI (n = 35) | ||||
| S100A8/A9USG | 0.671 | ≥96.3 | 96% | 43% |
| ≥8180.7 | 32% | 94% | ||
| S100A8/A9Cre | 0.612 | ≥160.0 | 96% | 35% |
| S100A12USG | 0.516 | ≤3.2 | 91% | 29% |
| S100A12Cre | 0.521 | ≤117.9 | 68% | 62% |
| uCalR | 0.751 | ≥9.1 | 91% | 60% |
| ≥5.2 | 100% | 49% | ||
| ≥72.2 | 18% | 94% | ||
| Treatment-naïve TCC/PCA vs. other diseases causing lower urinary tract signs (n = 45) | ||||
| S100A8/A9USG | 0.684 | ≥96.3 | 96% | 44% |
| ≥8230.7 | 32% | 96% | ||
| S100A8/A9Cre | 0.631 | ≥167.8 | 96% | 39% |
| S100A12USG | 0.548 | ≥7.0 | 82% | 42% |
| S100A12Cre | 0.517 | ≥8.7 | 96% | 34% |
| uCalR | 0.698 | ≥5.2 | 100% | 40% |
| ≥9.1 | 91% | 49% | ||
| ≥72.2 | 18% | 96% | ||
| Treatment-naïve TCC/PCA vs. other disease groups (n = 86)a | ||||
| S100A8/A9USG | 0.807 | ≥109.9 | 96% | 64% |
| ≥2274.8 | 36% | 92% | ||
| S100A8/A9Cre | 0.763 | ≥188.9 | 96% | 55% |
| ≥8603.1 | 27% | 91% | ||
| S100A12USG | 0.712 | ≥4.0 | 91% | 57% |
| ≥776.1 | 23% | 93% | ||
| S100A12Cre | 0.697 | ≥8.7 | 96% | 78% |
| ≥2538.9 | 18% | 95% | ||
| uCalR | 0.664 | ≥9.3 | 91% | 42% |
| ≥83.4 | 18% | 96% | ||
| Treatment-naïve TCC/PCA vs. all other groups (n = 119)a | ||||
| S100A8/A9USG | 0.824 | ≥109.9 | 96% | 66% |
| ≥2274.8 | 36% | 93% | ||
| S100A8/A9Cre | 0.787 | ≥188.9 | 96% | 59% |
| ≥5783.2 | 36% | 92% | ||
| S100A12USG | 0.740 | ≥7.0 | 82% | 66% |
| ≥221.0 | 27% | 90% | ||
| S100A12Cre | 0.722 | ≥8.7 | 96% | 57% |
| ≥833.8 | 23% | 90% | ||
| uCalR | 0.657 | ≥9.3 | 91% | 41% |
| ≥83.4 | 18% | 96% | ||
| Treatment-naïve TCC/PCA vs. all other groups, excl. Urinary tract infections (n = 84) | ||||
| S100A8/A9USG | 0.896 | ≥109.9 | 96% | 75% |
| ≥374.9 | 59% | 95% | ||
| S100A8/A9Cre | 0.875 | ≥188.9 | 96% | 70% |
| ≥792.7 | 55% | 91% | ||
| S100A12USG | 0.850 | ≥8.6 | 77% | 86% |
| ≥4.0 | 91% | 71% | ||
| S100A12Cre | 0.838 | ≥10.7 | 91% | 76% |
| ≥92.3 | 32% | 91% | ||
| uCalR | 0.612 | ≥9.3 | 91% | 33% |
aexcluding TCC/PCA dogs undergoing anticancer therapy
†values in boldface are significant at P < 0.05